Table 1.
Non-exhaustive list of clinical studies using the γ-H2AX assay to measure the effects of chemotherapeutic drugs in cancer patients. The top of the table includes published clinical studies while the bottom part contains some studies obtained from the ClinicalTrials.gov database
| Tissues analyzed | Drug(s) | Condition | γ-H2AX detection | Phase | References |
|---|---|---|---|---|---|
| PBMCs | Clofarabine and cyclophosphamide | Refractory acute leukemias | FACS | I | [64] |
| PBMCs/tumor biopsies | SJG-136 | Solid tumours | M | I | [65] |
| AML marrow blasts | Combination of tipifarnib and etoposide | AML | FACS | I | [64] |
| PBMCs | Combination of 5-azacytidine and entinostat | MDS, chronic myelomonocytic leukemia, and AML | I | I | [68] |
| Plucked eye-brows | Olaparib (AZD2281) | Breast cancer | M | I | [39] |
| CTCs/PBMCs | Combination of veliparib (ABT-888) with topotecan | Solid tumours and lymphomas | M | I | [67] |
| ClinicalTrials.gov | |||||
| Tissues analyzed | Drug(s) | Condition | γ-H2AX detection | Phase | ClinicalTri als.gov identifier |
| PBMCs, skin, hairs | Veliparib (ABT-888) | Breast, ovarian, pancreatic, prostate cancers; BRCA1, BRCA2 mutations carriers | N/S | I | NCT008927 36 |
| Tumor biopsies | 7-t-butyldimethylsilyl-10-hydroxycamptothecin | Solid malignancies | M/I | I | NCT012023 70 |
| N/A | BSI-201 (Iniparib) | Advanced solid tumours | N/S | I | NCT011618 36 |
| N/A | Combination of BSI-201 and temozolomide | Glioblastoma | N/S | I, II | NCT006877 65 |
| N/A | BSI-201 (Iniparib) | Ovarian cancer | N/S | II | NCT010331 23 |
| N/A | TH-302 | Glioma | M/I | II | NCT014036 10 |
| N/A | Combination of gemcitabine, carboplatin and BSI-201 | Triple negative breast cancer | N/S | II | NCT008139 56 |
| N/A | Combination of gemcitabine/carboplatin plus BSI-201 | Breast cancer | N/S | III | NCT009386 52 |